Goodwin Procter LLP advised AbSci on the deal.AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The round…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now